https://odysseytrial.org/2016/09/21/first-patient-enrolled-in-odyssey-study/ 2019-03-15T10:49:21+00:00 https://odysseytrial.org/wp-content/uploads/2018/11/bill-wegener-285004-unsplash-768x530.jpg https://odysseytrial.org/2017/08/02/a-further-step-for-the-odyssey-trial/ 2019-03-15T10:49:28+00:00 https://odysseytrial.org/wp-content/uploads/2018/11/bill-wegener-285004-unsplash-768x530.jpg https://odysseytrial.org/2018/04/12/odyssey-b-has-completed-recruitment-with-395-children-enrolled/ 2019-03-15T10:49:34+00:00 https://odysseytrial.org/2018/06/29/odyssey-recruitment-has-completed/ 2019-03-15T10:49:41+00:00 https://odysseytrial.org/wp-content/uploads/2018/11/bill-wegener-285004-unsplash-768x530.jpg https://odysseytrial.org/wp-content/uploads/2018/11/bill-wegener-285004-unsplash-768x530.jpg https://odysseytrial.org/2019/07/30/ias-2019-oral-abstract-presented-on-odyssey-pk-study-2/ 2019-07-30T14:31:40+00:00 https://odysseytrial.org/wp-content/uploads/2019/07/ias2019-share-graphic-6.png https://odysseytrial.org/2019/08/26/odyssey-presentation-at-annual-conference-of-the-international-society-for-clinical-biostatistics/ 2019-08-26T09:55:44+00:00 https://odysseytrial.org/wp-content/uploads/2019/08/512x512bb.jpg https://odysseytrial.org/2019/10/23/recruitment-to-the-main-trial-is-complete/ 2019-10-23T13:32:02+00:00 https://odysseytrial.org/wp-content/uploads/2019/10/photo-1553204061-1e1df46aff30.jpeg https://odysseytrial.org/2019/12/20/data-from-odyssey-are-used-by-viiv-healthcare-to-file-fda-and-ema-submissions-for-the-first-ever-dispersible-formulation-of-dolutegravir-for-children-living-with-hiv/ 2020-01-18T17:36:35+00:00 https://odysseytrial.org/wp-content/uploads/2020/01/Slide444-1.jpeg https://odysseytrial.org/2020/01/24/analysing-small-groups-within-clinical-trials-while-borrowing-information-from-larger-groups/ 2020-01-24T13:44:46+00:00 https://odysseytrial.org/2020/01/24/pharmacokinetics-of-dolutegravir-5mg-dispersible-tablets-in-children-weighing-6-to/ 2020-01-24T13:46:33+00:00 https://odysseytrial.org/2020/01/27/adult-dolutegravir-50mg-film-coated-tablets-in-children-living-with-hiv-weighing-20-to/ 2020-01-27T14:10:11+00:00 https://odysseytrial.org/2020/01/27/steady-state-pharmacokinetics-and-early-safety-data-in-hiv-infected-african-children-weighing-14-to/ 2020-01-27T14:11:40+00:00 https://odysseytrial.org/2020/01/27/odyssey-design-current-status-and-baseline-characteristics/ 2020-01-27T14:12:58+00:00 https://odysseytrial.org/2020/03/13/adeqaute-dolutegravir-exposure-dosed-bid-with-rifampicin-in-children-6-to-18-years/ 2020-03-13T11:32:35+00:00 https://odysseytrial.org/2020/03/13/adeqaute-dolutegravir-exposure-dosed-bid-with-rifampicin-in-children-6-to-18-years-2/ 2020-03-13T11:33:14+00:00 https://odysseytrial.org/2018/07/21/steady-state-pharmacokinetics-and-early-safety-data-in-hiv-infected-african-children-weighing-%e2%89%a525kg-after-switching-to-50mg-film-coated-dolutegravir-tablets-in-the-odyssey-trial/ 2020-03-24T12:39:52+00:00 https://odysseytrial.org/2020/02/11/odyssey-to-be-presented-at-croi-2020-2/ 2020-03-24T14:28:43+00:00 https://odysseytrial.org/wp-content/uploads/2020/02/kisspng-conference-on-retroviruses-and-opportunistic-infec-conference-on-retroviruses-and-opportunistic-infec-5b1778254f21c8.0096183515282647413241.png https://odysseytrial.org/2020/05/21/odyssey-trials-covid-19-response-and-croi-update/ 2020-05-25T14:46:24+00:00 https://odysseytrial.org/wp-content/uploads/2020/05/covid.jpeg https://odysseytrial.org/2020/05/27/what-does-covid-19-mean-for-those-living-in-hiv-communities/ 2020-05-27T08:34:03+00:00 https://odysseytrial.org/wp-content/uploads/2020/05/Screenshot-2020-05-27-at-10.31.21.png https://odysseytrial.org/2020/06/29/odyssey-trial-plays-an-important-role-in-the-fda-approval-of-dolutegravir-for-children-a-big-step-towards-timely-access-to-optimal-art-for-children/ 2020-06-29T13:31:40+00:00 https://odysseytrial.org/wp-content/uploads/2020/06/Screenshot-2020-06-29-at-15.00.10.png https://odysseytrial.org/2020/06/29/dolutegravir-for-children-living-with-hiv/ 2020-07-03T11:39:23+00:00 https://odysseytrial.org/wp-content/uploads/2020/06/Screenshot-2020-06-29-at-15.18.30.png https://odysseytrial.org/2020/08/06/simplified-dolutegravir-dosing-for-children-with-hiv-weighing-20-kg-or-more-pharmacokinetic-and-safety-substudies-of-the-multicentre-randomised-odyssey-trial/ 2020-08-06T09:16:41+00:00 https://odysseytrial.org/2020/08/06/odyssey-trial-data-published-in-lancet-shows-increase-in-treatment-options-for-older-children-living-with-hiv/ 2020-11-24T13:23:14+00:00 https://odysseytrial.org/wp-content/uploads/2020/08/wayne-lee-sing-zYZZf6ZSEwI-unsplash-scaled.jpeg https://odysseytrial.org/2020/11/19/european-medicines-agency-approves-use-of-dolutegravir-5-mg-dispersible-tablet-for-younger-children-living-with-hiv/ 2020-11-24T15:32:47+00:00 https://odysseytrial.org/wp-content/uploads/2020/11/nathan-dumlao-zBSa4JpAiKo-unsplash-scaled.jpg https://odysseytrial.org/2020/12/21/cheaper-hiv-treatment-for-children-a-report-in-the-lancet/ 2020-12-21T09:55:53+00:00 https://odysseytrial.org/wp-content/uploads/2020/12/Screen-Shot-2020-12-21-at-10.54.43.png https://odysseytrial.org/2021/02/19/odyssey-clinical-trial-design-a-randomised-global-study-to-evaluate-the-efficacy-and-safety-of-dolutegravir-based-antiretroviral-therapy-in-hiv-positive-children-with-nested-pharmacokinetic-sub-stud/ 2021-02-19T14:57:32+00:00 https://odysseytrial.org/2021/02/17/new-european-african-project-that-will-develop-universal-treatments-for-children-living-with-hiv/ 2021-02-23T11:53:53+00:00 https://odysseytrial.org/2021/01/21/eu-grants-marketing-authorisation-to-first-ever-dispersible-tablet-dolutegravir/ 2021-02-25T11:06:00+00:00 https://odysseytrial.org/wp-content/uploads/2021/01/pexels-cottonbro-4715329-1-scaled.jpg https://odysseytrial.org/2021/03/11/dolutegravir-based-art-is-superior-to-nnrti-pi-based-art-in-children-and-adolescents-2/ 2021-03-11T14:24:04+00:00 https://odysseytrial.org/2021/03/11/odyssey-trial-finds-new-drug-is-better-for-treating-children-living-with-hiv/ 2021-03-22T13:26:47+00:00 https://odysseytrial.org/wp-content/uploads/2020/06/Screenshot-2020-06-29-at-15.18.30.png https://odysseytrial.org/2021/03/22/odyssey-team-at-radboud-receives-the-rihs-societal-award-2020/ 2021-03-22T13:46:23+00:00 https://odysseytrial.org/wp-content/uploads/2021/03/Screen-Shot-2021-03-22-at-14.16.23.png https://odysseytrial.org/2021/03/22/because-we-all-have-to-grow-up-supporting-adolescents-to-develop-core-competencies-to-transition-towards-managing-their-hiv-independently/ 2021-03-22T15:54:09+00:00 https://odysseytrial.org/2018/07/21/i-failed-to-take-them-as-i-should-and-now-im-scared-how-can-we-support-adolescents-adherence-on-second-line-hiv-treatment/ 2021-04-12T09:23:57+00:00 https://odysseytrial.org/2021/07/29/neuropsychiatric-manifestations-and-sleep-disturbances-in-children-and-adolescents-randomised-todolutegravir-based-art-vs-standard-of-care-in-the-odyssey-trial/ 2021-07-29T13:47:27+00:00 https://odysseytrial.org/2021/07/29/neuropsychiatric-manifestations-and-sleep-disturbances-in-children-and-adolescents-randomised-todolutegravir-based-art-vs-standard-of-care-in-the-odyssey-trial-2/ 2021-07-29T13:48:14+00:00 https://odysseytrial.org/2021/07/29/no-age-related-difference-in-dolutegravir-metabolic-glucuronidation-ratio-in-children-between-3-months-and-18-years-old-in-the-odyssey-trial/ 2021-07-29T13:48:54+00:00 https://odysseytrial.org/2021/07/29/effect-of-dolutegravir-on-folate-and-vitamin-b12-status-among-hiv-infected-children-and-adolescents-in-the-odyssey-trial-2/ 2021-07-29T13:49:22+00:00 https://odysseytrial.org/2021/07/29/effect-of-dolutegravir-on-folate-and-vitamin-b12-status-among-hiv-infected-children-and-adolescents-in-the-odyssey-trial/ 2021-07-29T13:49:46+00:00 https://odysseytrial.org/2021/07/29/a-randomised-comparison-of-dtg-based-art-vs-standard-of-care-in-infants-and-young-children-living-with-hiv-weighing-3-to-14kg-results-from-the-odyssey-trial/ 2021-07-29T13:57:58+00:00 https://odysseytrial.org/2021/07/29/dolutegravir-based-art-is-superior-to-standard-of-care-in-young-children-living-with-hiv/ 2021-07-29T14:02:13+00:00 https://odysseytrial.org/2021/07/16/new-findings-from-the-odyssey-trial-confirm-superiority-of-dolutegravir-based-art-in-younger-children/ 2021-08-12T13:43:50+00:00 https://odysseytrial.org/wp-content/uploads/2021/07/SHIELD-PPT-20.png https://odysseytrial.org/2021/09/28/dolutegravir-based-art-is-superior-to-standard-of-care-in-young-children-living-with-hiv-combined-results-of-the-main-trial-and-the-under-14kg-cohort/ 2021-09-28T14:25:18+00:00 https://odysseytrial.org/2021/10/29/odyssey-trial-wins-2021-hector-award/ 2021-11-08T09:17:35+00:00 https://odysseytrial.org/wp-content/uploads/2021/10/Screenshot-2021-10-29-at-14.53.32.png https://odysseytrial.org/2021/12/30/easy-to-take-medicine-better-at-suppressing-hiv-in-children/ 2021-12-30T11:30:16+00:00 https://odysseytrial.org/wp-content/uploads/2021/12/ODYSSEY-PR.jpg https://odysseytrial.org/2019/03/14/adult-dolutegravir-could-offer-a-practical-and-accessible-treatment-for-children-living-with-hiv/ 2022-01-17T07:01:17+00:00 https://odysseytrial.org/wp-content/uploads/2019/03/Odysseytrial-at-CROI.png https://odysseytrial.org/2022/02/21/borrowing-information-across-patient-subgroups-in-clinical-trials-with-application-to-a-paediatric-trial/ 2022-02-21T13:32:41+00:00 https://odysseytrial.org/2022/08/03/voluntary-consent-to-research-on-hiv-infected-children-in-the-chapas-4-and-odyssey-hiv-clinical-trials-abstract/ 2022-08-03T10:11:06+00:00 https://odysseytrial.org/2022/08/31/dolutegravir-based-hiv-treatment-is-better-for-babies-and-young-children/ 2022-08-31T10:45:18+00:00 https://odysseytrial.org/wp-content/uploads/2020/06/Screenshot-2020-06-29-at-15.18.30.png https://odysseytrial.org/2022/08/31/once-daily-dolutegravir-based-antiretroviral-therapy-in-infants-and-children-living-with-hiv-from-age-4-weeks-results-from-the-below-14-kg-cohort-in-the-randomised-odyssey-trial/ 2022-08-31T12:17:07+00:00 https://odysseytrial.org/2022/07/20/double-dose-of-dolutegravir-to-treat-hiv-in-children-also-being-treated-for-tuberculosis/ 2022-10-03T15:01:38+00:00 https://odysseytrial.org/wp-content/uploads/2022/07/ODYSSEY-DTG-TB-treatment.png https://odysseytrial.org/2021/09/15/virological-failures-and-genotypic-resistance-in-children-and-adolescents-randomised-to-dolutegravir-based-art-vs-standard-of-care-in-the-main-odyssey-trial-%e2%89%a514kg/ 2022-11-11T09:03:42+00:00 https://odysseytrial.org/2021/09/15/dolutegravir-based-art-is-superior-to-nnrti-and-pi-based-art-in-infants-children-and-adolescents-living-with-hivcombined-results-of-the-main-trial-and-the-under-14kg-cohort/ 2022-11-11T09:06:55+00:00 https://odysseytrial.org/2021/07/22/neuropsychiatric-manifestations-and-sleep-disturbances-in-children-and-adolescents-randomised-todolutegravir-based-art-vs-standard-of-care-in-the-odyssey-trial-3/ 2022-11-11T09:22:06+00:00 https://odysseytrial.org/2021/07/21/effect-of-dolutegravir-on-folate-and-vitamin-b12-status-among-hiv-infected-children-and-adolescents-in-the-odyssey-trial-3/ 2022-11-11T09:27:21+00:00 https://odysseytrial.org/2022/07/21/weight-gain-in-children-and-adolescents-on-dolutegravir-vs-standard-of-care-in-the-odyssey-trial/ 2022-11-11T09:46:43+00:00 https://odysseytrial.org/2022/07/21/virological-failures-and-genotypic-resistance-in-children-and-adolescents-randomised-to-dolutegravir-based-art-vs-standard-of-care-in-the-odyssey-trial-2/ 2022-11-11T09:52:00+00:00 https://odysseytrial.org/2021/07/21/a-randomised-comparison-of-dtg-based-art-vs-standard-of-care-in-infants-and-young-children-living-with-hiv-weighing-3-to-14kg-results-from-the-odyssey-trial-2/ 2022-11-11T10:05:30+00:00 https://odysseytrial.org/2021/12/11/dolutegravir-based-art-is-superior-to-standard-of-care-artin-young-children/ 2022-11-11T10:24:50+00:00 https://odysseytrial.org/2022/07/29/voluntary-consent-to-research-on-hiv-infected-children-in-the-chapas-4-and-odyssey-hiv-clinical-trials/ 2022-11-11T11:09:00+00:00 https://odysseytrial.org/2021/12/30/dolutegravir-as-first-or-second-line-treatment-for-hiv-1-infection-in-children/ 2023-05-18T07:10:46+00:00 https://odysseytrial.org/2022/02/21/dolutegravir-dosing-for-children-with-hiv-weighing-less-than-20-kg-pharmacokinetic-and-safety-substudies-nested-in-the-open-label-multicentre-randomised-non-inferiority-odyssey-trial-2/ 2023-05-18T07:12:14+00:00 https://odysseytrial.org/2021/07/29/virological-failures-and-genotypic-resistance-in-children-and-adolescents-randomised-to-dolutegravir-based-art-vs-standard-of-care-in-the-odyssey-trial/ 2023-05-18T07:17:04+00:00 https://odysseytrial.org/2020/08/31/simplified-dolutegravir-dosing-for-children-with-hiv-weighing-20-kg-or-more-pharmacokinetic-and-safety-substudies-of-the-multicentre-randomised-odyssey-trial-2/ 2023-08-09T08:23:44+00:00 https://odysseytrial.org/2021/01/04/odyssey-clinical-trial-design-a-randomised-global-study-to-evaluate-the-efficacy-and-safety-of-dolutegravir-based-antiretroviral-therapy-in-hiv-positive-children-with-nested-pharmacokinetic-sub-stud-2/ 2023-08-09T08:27:27+00:00 https://odysseytrial.org/2023/08/09/neuropsychiatric-manifestations-and-sleep-disturbances-with-dolutegravir-based-antiretroviral-therapy-versus-standard-of-care-in-children-and-adolescents-a-secondary-analysis-of-the-odyssey-trial/ 2023-08-09T09:01:09+00:00 https://odysseytrial.org/2023/09/28/effect-of-dolutegravir-on-folate-vitamin-b12-and-mean-corpuscular-volume-levels-among-children-and-adolescents-with-hiv-a-sub-study-of-the-odyssey-randomized-controlled-trial/ 2023-09-28T10:00:17+00:00 https://odysseytrial.org/2024/03/07/odyssey-192-week-follow-up-evidences-superior-efficacy-of-dtg-for-children-on-first-second-line-art/ 2024-03-07T13:21:38+00:00 https://odysseytrial.org/2025/02/19/virological-outcomes-and-genotypic-resistance-on-dolutegravir-based-antiretroviral-therapy-versus-standard-of-care-in-children-and-adolescents-a-secondary-analysis-of-the-odyssey-trial/ 2025-02-24T11:12:42+00:00 https://odysseytrial.org/2025/07/17/efficacy-of-second-line-dolutegravir-versus-boosted-protease-inhibitor-based-art-in-children-and-adolescents-living-with-hiv-at-96-and-144-weeks-pooled-analysis-of-the-odyssey-and-chapas-4-trials/ 2025-07-17T08:33:05+00:00 https://odysseytrial.org/2025/07/23/predictors-of-treatment-failure-in-children-living-with-hiv-starting-first-line-antiretroviral-therapy-in-the-odyssey-trial/ 2025-07-23T09:05:55+00:00 https://odysseytrial.org/2025/07/24/pregnancies-among-adolescents-and-young-women-on-dolutegravir-vs-standard-of-care-in-the-odyssey-trial-and-effects-of-the-dolutegravir-neural-tube-defect-safety-alert/ 2025-07-24T06:23:49+00:00 https://odysseytrial.org/2025/07/24/growth-trajectories-before-and-after-switching-to-dolutegravir-in-children-living-with-hiv-in-the-odyssey-trial/ 2025-07-24T08:27:39+00:00 https://odysseytrial.org/2026/02/02/weight-gain-body-composition-and-metabolic-parameters-of-dolutegravir-based-antiretroviral-therapy-versus-standard-of-care-in-children-and-adolescents-an-ancillary-analysis-of-the-odyssey-trial/ 2026-02-02T08:15:44+00:00 https://odysseytrial.org/2026/02/02/weight-gain-body-composition-and-metabolic-parameters-of-dolutegravir-based-antiretroviral-therapy-versus-standard-of-care-in-children-and-adolescents-an-ancillary-analysis-of-the-odyssey-trial-2/ 2026-02-02T08:16:44+00:00 https://odysseytrial.org/2026/04/20/wyncoll-j-kamolrattana-r-archary-m-mujuru-ha-kekitiinwa-ar-violari-a-na-rajsima-s-lugemwa-a-variava-e-cotton-m-kityo-cm-konigs-c-behuhuma-no-welch-s-saidi-y-marques-l-ahimbisibwe-gm-h/ 2026-04-20T08:02:36+00:00 https://odysseytrial.org/2026/06/05/dolutegravir-as-first-or-second-line-treatment-for-children-with-hiv-240-week-follow-up-of-the-odyssey-randomized-trial/ 2026-06-05T15:26:12+00:00 https://odysseytrial.org/2026/07/26/t-cell-subsets-t-cell-receptor-repertoire-and-hiv-1-virological-reservoir-in-children-initiating-first-line-dolutegravir-versus-standard-of-care-art-results-from-the-odyssey-trial/ 2026-07-28T12:07:38+00:00 https://odysseytrial.org/2026/07/26/predictors-of-viral-rebound-in-children-living-with-hiv-initiating-second-line-antiretroviral-therapy-in-the-odyssey-and-chapas-4-trials/ 2026-08-28T13:09:26+00:00